Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Nov 18, 2019
– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –
Co-Commercialize Product Candidates –
– Dicerna to Receive Upfront Payment of
Equity Investment of
– Dicerna is Eligible to Receive an Additional
– Dicerna to Host Conference Call Today at
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005269/en/
The agreement represents a significant investment by
“We are excited to collaborate with
The agreement enables each company to co-develop and co-commercialize product candidates discovered under the collaboration.
“Through this important collaboration with Dicerna, we gain access to an innovative technology and deep expertise in RNA interference,” said
Under the terms of the agreement, Dicerna will receive:
An upfront payment of
USD 175 million.
USD 50 millionequity investment in Dicerna at a premium.
USD 25 millionannually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets.
USD 357.5 millionper target in development, regulatory, and commercialization milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens.
The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.
Dicerna Conference Call and Webcast Today
Dicerna management will host a conference call and webcast today,
About Dicerna's GalXC™ RNAi Technology Platform
Dicerna’s proprietary RNA interference (RNAi) technology platform, called GalXC™, aims to advance the development of next-generation RNAi-based therapies designed to silence disease-driving genes in the liver and other tissues. Liver-targeted GalXC-based compounds enable subcutaneous delivery of RNAi therapies that are designed to bind specifically to receptors on liver cells, leading to internalization and access to the RNAi machinery within the cells. The GalXC approach seeks to optimize the activity of the RNAi pathway so that it operates in the most specific and potent fashion. Compounds produced via GalXC are intended to be broadly applicable across multiple therapeutic areas, including both liver and non-liver indications.
Dicerna Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements include, among others, statements we make regarding: (i) the full potential to leverage our GalXC platform to target and silence specific genes that contribute to cardio-metabolic diseases; (ii) the potential to earn revenue from royalties and milestone payments under the collaboration with
Dicerna™ and GalXC™ are trademarks of
Alex Van Rees, SmithSolve
Media Novo Nordisk:
Mette Kruse Danielsen
+45 3079 3883
Ken Inchausti (US)
+1 609 240 9429
Lauren Stival, Stern Investor Relations, Inc.
Investors Novo Nordisk:
Peter Hugreffe Ankersen
+45 3075 9085
Valdemar Borum Svarrer
+45 3079 0301
Ann Søndermølle Rendbæk
+45 3075 2253
Mark Joseph Root
+45 3079 4211
Kristoffer Due Berg (US)
+1 609 235 2989